Pear Therapeutics (PEARQ) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39969
Entity Registrant Name	Pear Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	200 State Street
Entity Address, Address Line Two	13th Floor
Entity Address, State or Province	MA
Entity Address, City or Town	Boston
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	925-7848
Entity Tax Identification Number	85-4103092
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		138,768,704
Amendment Flag	false
Entity Central Index Key	0001835567
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Class A Common Stock
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	PEAR
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Class A common stock for $11.50 per share
Trading Symbol	PEARW
Security Exchange Name	NASDAQ

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 60,185	$ 169,567
Short-term investments	46,922	5,004
Restricted cash - short-term	66	0
Accounts receivable	5,377	1,794
Prepaid expenses and other current assets	8,320	8,876
Total current assets	120,870	185,241
Property and equipment, net	6,642	6,255
Right-of-use assets (Note 8)	9,768	0
Restricted cash - long-term	411	411
Other long-term assets	4,828	5,253
Total assets	142,519	197,160
Current liabilities:
Accounts payable	2,040	1,806
Accrued expenses and other current liabilities	15,071	17,946
Lease liabilities - current (Note 8)	1,821	0
Deferred revenues	680	421
Debt	27,354	26,993
Total current liabilities	46,966	47,166
Lease liabilities - noncurrent (Note 8)	9,217	0
Embedded debt derivative	123	675
Warrant liabilities	1,795	8,528
Earn-out liabilities	4,573	48,363
Other long-term liabilities	805	1,994
Total liabilities	63,479	106,726
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2022; and no shares issued and outstanding as of June 30, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value; 690,000,000 authorized as of June 30, 2022; and 138,677,770 and 137,836,028 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	14	14
Additional paid-in capital	345,526	338,404
Accumulated deficit	(266,380)	(247,983)
Accumulated other comprehensive (loss) income	(120)	(1)
Total stockholders’ equity	79,040	90,434
Total liabilities and stockholders’ equity	$ 142,519	$ 197,160

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	690,000,000
Common stock, issued (in shares)	138,677,770	137,836,028
Common stock, outstanding (in shares)	138,677,770	137,836,028

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue
Total revenue	$ 3,297	$ 1,201	$ 6,046	$ 1,577
Cost of Revenue	2,401	727	3,882	1,465
Cost and operating expenses
Research and development	12,716	7,877	25,980	15,367
Selling, general, and administrative	21,000	14,546	43,745	27,845
Total cost and operating expenses	36,117	23,150	73,607	44,677
Loss from operations	(32,820)	(21,949)	(67,561)	(43,100)
Other income (expense):
Interest and other (expense) income, net	(343)	(1,018)	(1,359)	(2,044)
Change in estimated fair value of earn-out liabilities	29,163	0	43,790	0
Change in estimated fair value of warrant liabilities	9,462	(5,234)	6,733	(5,397)
Loss on issuance of Legacy Pear convertible preferred stock	0	0	0	(2,053)
Total other income (expense)	38,282	(6,252)	49,164	(9,494)
Net income (loss)	5,462	(28,201)	(18,397)	(52,594)
Unrealized gain (loss) on short-term investments	(77)	1	(119)	1
Comprehensive income (loss)	$ 5,385	$ (28,200)	$ (18,516)	$ (52,593)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.04	$ (0.25)	$ (0.13)	$ (0.48)
Diluted (in dollars per share)	$ 0.04	$ (0.25)	$ (0.13)	$ (0.48)
Weighted average common shares outstanding:
Weighted-average common shares outstanding, basic (in shares)	138,288,357	111,946,894	138,071,377	110,311,459
Weighted-average common shares outstanding, diluted (in shares)	147,422,043	111,946,894	138,071,377	110,311,459
Product revenue
Revenue
Total revenue	$ 2,997	$ 1,047	$ 5,746	$ 1,347
Collaboration and license revenue
Revenue
Total revenue	$ 300	$ 154	$ 300	$ 230

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2020		106,721,878
Beginning balance at Dec. 31, 2020	$ 87,116	$ 11	$ 269,946	$ (182,841)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible preferred stock to common stock (in shares)		4,503,618
Conversion of convertible preferred stock to common stock	21,970		21,970
Exercise of common stock options (in shares)		642,489
Exercise of common stock options	402		402
Stock-based compensation expense	463		463
Net income (loss)	(24,393)			(24,393)
Ending balance at Mar. 31, 2021	85,558	$ 11	292,781	(207,234)	0
Ending balance (in shares) at Mar. 31, 2021		111,867,985
Beginning balance (in shares) at Dec. 31, 2020		106,721,878
Beginning balance at Dec. 31, 2020	87,116	$ 11	269,946	(182,841)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(52,594)
Ending balance at Jun. 30, 2021	58,197	$ 11	293,620	(235,435)	1
Ending balance (in shares) at Jun. 30, 2021		112,153,183
Beginning balance (in shares) at Mar. 31, 2021		111,867,985
Beginning balance at Mar. 31, 2021	85,558	$ 11	292,781	(207,234)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		285,198
Exercise of common stock options	267		267
Stock-based compensation expense	572		572
Other comprehensive income	1				1
Net income (loss)	(28,201)			(28,201)
Ending balance at Jun. 30, 2021	58,197	$ 11	293,620	(235,435)	1
Ending balance (in shares) at Jun. 30, 2021		112,153,183
Beginning balance (in shares) at Dec. 31, 2021		137,836,028
Beginning balance at Dec. 31, 2021	90,434	$ 14	338,404	(247,983)	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		65,145
Exercise of common stock options	75		75
Stock-based compensation expense	2,901		2,901
Exercise of common stock warrants (in shares)		10
Other comprehensive income	(42)				(42)
Net income (loss)	(23,859)			(23,859)
Ending balance at Mar. 31, 2022	69,509	$ 14	341,380	(271,842)	(43)
Ending balance (in shares) at Mar. 31, 2022		137,901,183
Beginning balance (in shares) at Dec. 31, 2021		137,836,028
Beginning balance at Dec. 31, 2021	$ 90,434	$ 14	338,404	(247,983)	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)	841,732
Net income (loss)	$ (18,397)
Ending balance at Jun. 30, 2022	79,040	$ 14	345,526	(266,380)	(120)
Ending balance (in shares) at Jun. 30, 2022		138,677,770
Beginning balance (in shares) at Mar. 31, 2022		137,901,183
Beginning balance at Mar. 31, 2022	69,509	$ 14	341,380	(271,842)	(43)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		776,587
Exercise of common stock options	760		760
Stock-based compensation expense	3,386		3,386
Other comprehensive income	(77)				(77)
Net income (loss)	5,462			5,462
Ending balance at Jun. 30, 2022	$ 79,040	$ 14	$ 345,526	$ (266,380)	$ (120)
Ending balance (in shares) at Jun. 30, 2022		138,677,770

UNAUDITED CONDENSED CONSOLIDA_5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Preferred Stock | Convertible Preferred Stock
Issuance costs	$ 83

UNAUDITED CONDENSED CONSOLIDA_6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities:
Net income (loss)	$ (18,397)	$ (52,594)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,540	585
Amortization of intangible asset	310	138
Amortization of debt discount	360	309
Amortization of right-of-use asset	846	0
Accretion and amortization of interest income	(50)	14
Stock-based compensation expense	6,287	1,035
Loss on issuance of Legacy Pear convertible preferred stock	0	2,055
Change in fair value of warrants	(6,733)	5,396
Change in fair value of earn-out liabilities	(43,790)	0
Change in fair value of embedded derivative	(552)	0
Changes in operating assets and liabilities:
Accounts receivable	(3,583)	99
Prepaid expenses and other assets	671	(505)
Lease liabilities	(821)	0
Accounts payable	127	(2,063)
Accrued expenses, other liabilities and non-current liabilities	(2,823)	626
Deferred revenues	263	1,039
Net cash used in operating activities	(66,345)	(43,866)
Investing Activities:
Proceeds from maturities of short-term investments	24,048	12,025
Purchases of short-term investments	(66,035)	(5,018)
Purchases of property and equipment	(1,820)	(1,504)
Net cash provided by (used in) investing activities	(43,807)	5,503
Financing Activities:
Proceeds from issuance of Legacy Pear convertible preferred stock, net	0	19,915
Payment of deferred offering costs	0	(902)
Proceeds from exercise of stock options	836	669
Net cash provided by financing activities	836	19,682
Net decrease in cash, cash equivalents and restricted cash	(109,316)	(18,681)
Cash, cash equivalents and restricted cash—beginning of period	169,978	112,061
Cash, cash equivalents and restricted cash—end of period	60,662	93,380
Supplemental disclosure of cash flow information:
Cash paid for interest	1,812	1,810
Supplemental disclosure of non-cash investing and financing information:
Deferred offering and equity issuance costs included in accounts payable and accrued expenses	0	2,600
Purchases of property and equipment in accounts payable and accrued expenses	$ 281	$ 8

NATURE OF BUSINESS

NATURE OF BUSINESS	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	NATURE OF BUSINESS Basis of Presentation References throughout this Form 10-Q to “we,” “us,” the “Company,” “Pear” or “our company” are to Pear Therapeutics, Inc. (formerly known as Thimble Point Acquisition Corp.) and its subsidiaries, and “Legacy Pear” refers to Pear Therapeutics (US), Inc. prior to the Business Combination, unless otherwise noted or the context otherwise indicates. References to THMA refer to the Company prior to the consummation of the Business Combination and references to “Legacy Pear” refer to Pear Therapeutics, Inc. (now Pear Therapeutics (US), Inc.) prior to the consummation of the Business Combination. Legacy Pear is deemed the accounting predecessor and the post-company successor SEC registrant, which means Legacy Pear financial statements for previous periods are disclosed in this Form 10-Q. Future period reports filed with the SEC will include Pear Therapeutics, Inc. and its subsidiaries. Organization Pear is a leader in prescription digital therapeutics, or PDTs. The Company’s PDTs treat diseases with clinically validated software. On December 3, 2021, (the “Closing Date”), we consummated a business combination, or the “Business Combination”, pursuant to the terms of the business combination agreement, or “Business Combination Agreement”, dated June 21, 2021, by and among the Company (formerly known as Thimble Point Acquisition Corp., or “THMA”), Pear Therapeutics (US), Inc., a Delaware corporation incorporated on August 14, 2013 (“Pear US”) (formerly known as Pear Therapeutics, Inc.) and Oz Merger Sub, Inc., pursuant to which Oz Merger Sub., Inc. (a Delaware corporation and wholly-owned subsidiary of THMA, or “Merger Sub”) merged with and into Pear US, with Pear US surviving as our wholly owned subsidiary. Upon the closing of the Business Combination, THMA changed its name to Pear Therapeutics, Inc. (“Pear” or the “Company”). Pursuant to the terms of the Business Combination Agreement, each share of Legacy Pear common stock, par value $0.0001 per share (“ Legacy Pear Common Shares ”) issued and outstanding immediately prior to the closing of the Business Combination, after giving effect to the conversion of all issued and outstanding shares of Legacy Pear preferred stock, par value $0.0001 per share (“ Legacy Pear Preferred Shares ”) to Legacy Pear Common Shares, were canceled and converted into the right to receive a number of shares of Class A common stock, par value $0.0001 per share (“ Class A common stock ”) equal to the number of shares of Legacy Pear Common Shares multiplied by the exchange ratio of approximately 1.47. In addition, all outstanding equity awards of Legacy Pear were converted into equity awards with the option to purchase Class A common stock with the same terms and conditions adjusted by the exchange ratio of approximately 1.47. In connection with the Business Combination, THMA completed the sale and issuance of 10,280,000 shares of Class A common stock in a fully committed common stock private placement at a purchase price of $10.00 per share (“PIPE Shares”) for an aggregate purchase price of $102,800 (“PIPE Investment”), and a Forward Purchase Agreement Assignment, dated as of December 2, 2021, by and among THMA, the Anchor Investor, and a Pipe Investor (the “Forward Purchase Assignment”); which closed simultaneously with the consummation of the Business Combination. Upon the closing of the Business Combination, all of the remaining outstanding THMA Class A common shares were separated, pursuant to their terms, into one share of Class A common stock (which totaled 832,899 shares Class A common stock, “Public Shares”) and one-third (1/3) of one redeemable warrant (and THMA’s units ceased trading on the Nasdaq). Further, KLP SPAC 1 LLC (the “Anchor Investor”) purchased 6,387,026 shares of Class A common stock at a purchase price of $10.00 per share in connection with the Forward Purchase Agreement, dated as of February 1, 2021, by and between THMA and the Anchor Investor (the “Forward Purchase Agreement”), as amended from time to time, including by the Amendment to Forward Purchase Agreement dated as of June 21, 2021, and the Second Amendment to Forward Purchase Agreement dated as of November 14, 2021 (the “Amended Forward Purchase Agreement”), entered into with THMA on February 1, 2021 (“THMA Sponsor Shares”). Gross proceeds from the Merger totaled approximately $175,001 which included funds held in THMA’s trust account (after giving effect to redemptions). Transaction costs totaled approximately $32,779. Legacy Pear was deemed the accounting acquirer in the Business Combination. This determination was primarily based on Legacy Pear’s stockholders prior to the Business Combination having a majority of the voting power in the combined company, Legacy Pear having the ability to appoint a majority of the Board of Directors of the combined company, Legacy Pear’s existing management comprising the senior management of the combined company, Legacy Pear comprising the ongoing operations of the combined company, Legacy Pear being the larger entity based on historical revenues and business operations, and the combined company assuming Legacy Pear’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy Pear issuing stock for the net assets of THMA, accompanied by a recapitalization. Under this method of accounting, THMA who was the legal acquirer, is treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Pear issuing stock for the net assets of THMA, accompanied by a recapitalization. The net assets of THMA are stated at historical cost, with no goodwill or other intangible assets recorded. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s Class A common stock, $0.0001 par value per share, issued to Legacy Pear stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Pear’s Convertible Preferred Stock (“ Legacy Pear Preferred Shares ”) and Legacy Pear common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 1.47 established in the Business Combination. Legacy Pear’s convertible preferred stock previously classified as mezzanine was retroactively adjusted, converted into Class A common stock, and reclassified to permanent as a result of the reverse recapitalization. See Note 3 for more information. THMA, now Pear Therapeutics, Inc., a Delaware corporation was incorporated on December 1, 2020. Pear Therapeutics (US), Inc., previously known as Pear Therapeutics, Inc. (“ Legacy Pear ”), is a Delaware corporation incorporated on August 14, 2013. The Company is headquartered in Boston, Massachusetts. Going Concern The Company is subject to a number of risks and uncertainties common to early-stage technology-based companies, including, but not limited to, rapid technological changes, protection of its proprietary technology and intellectual property, commercialization of existing and new products, development by competitors of competing products, dependence on key personnel, compliance with government regulations, including compliance with the US. Food and Drug Administration, or FDA, and the ability to secure additional capital to fund operations. The Company obtained FDA marketing authorization for its three products, reSET® (2017), reSET-O® (2018), and Somryst® (2020). In October 2019, after terminating our agreement with Sandoz Inc., our then collaboration partner, we began the direct commercialization of reSET® and reSET-O®. The Company has incurred recurring losses since inception and anticipates net losses and negative operating cash flows for the near future and may be unable to remain in compliance with certain financial covenants required under its credit facility. For the six months ended June 30, 2022, the Company had a net loss of $18,397 and as of June 30, 2022, had an accumulated deficit of $266,380. As of June 30, 2022, the Company had $107,107 of cash and cash equivalents and short-term investments. While the Company has recorded revenue, revenues have been insufficient to fund operations. Accordingly, the Company has funded its operations to date through a combination of proceeds raised from equity and debt issuances, including the Business Combination. The Company’s operating costs include the cost of developing and commercializing products as well as providing research services. As a consequence, the Company will need to raise additional equity and debt financing that may not be available, if at all, at terms acceptable to the Company to fund future operations. As a result, the Company could be required to delay, scale back or abandon some or all of its development programs and other operations, which could materially harm the Company’s business, prospects, financial condition and operating results. Management believes these uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. Because of these uncertainties, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Due to the substantial doubt about the Company’s ability to continue operating as a going concern for twelve months from the issuance date of these financial statements and the material adverse change clause in the Perceptive Credit Facility, the amounts due as of June 30, 2022, have been classified as current in the consolidated balance sheet. The lender has not invoked the material adverse change clause as of the date of issuance of these financial statements. The accompanying consolidated financial statements do not reflect any other adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company is subject to various covenants related to the Perceptive Credit Facility entered into on June 30, 2020, and given the substantial doubt about the Company’s ability to continue as a going concern, there is a risk that it may not meet its covenants in the future. COVID-19 Related Significant Risks and Uncertainties There continues to be uncertainties regarding the pandemic of the novel coronavirus, or COVID-19. The Company is closely monitoring the continued impact of COVID-19 on all aspects of its business, including how it will impact its customers, patients, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-19 may have on its business, financial position, and operations moving forward due to the numerous uncertainties. Any estimates made herein may change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB. The consolidated financial statements as of June 30, 2022 and 2021, and for the three and six months ended June 30, 2022 and 2021, include the accounts of Pear and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements herein. Certain monetary amounts, percentages, and other figures included elsewhere in these consolidated financial statements have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages that precede them. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and various other assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates and changes in estimates are reflected in reported results in the period in which they become known. Cash, Cash Equivalents, and Restricted Cash The Company considers only those highly liquid investments, readily convertible to cash, that mature within 90 days from the date of purchase to be cash equivalents. The Company’s cash equivalents include money market funds, commercial paper, and overnight deposits. The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows: June 30, 2022 December 31, 2021 Reconciliation of cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 60,185 $ 169,567 Restricted cash - short-term 66 — Restricted cash - long-term 411 411 Total cash, cash equivalents, and restricted cash $ 60,662 $ 169,978 Recently Adopted Accounting Pronouncements In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842) , as subsequently amended, which provides guidance requiring lessees to recognize a right-of-use asset (“ ROU ”) and a lease liability on the balance sheet for substantially all leases, with the exception of short-term leases. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of operations. The Company adopted the leasing standard effective January 1, 2022, using the revised modified retrospective transition method, with comparative periods continuing to be reported under ASC 840 as it was the accounting standard in effect for such period. In the adoption of ASU 2016-02, the Company carried forward the assessment from ASC 840 of whether its contracts contain or are leases, the classification of its leases, and remaining lease terms. The Company did not elect the hindsight practical expedient upon adoption of the new standard. The most significant impact resulting from the adoption of this new standard was the recognition of ROU assets of $10,614 and operating lease liabilites of $11,860 on the adoption date, January 1, 2022. The difference between the ROU assets and lease liabilities on the accompanying condensed consolidated balance sheet is primarily due to the accrual for lease payments as a result of straight-line lease expense and unamortized tenant incentive liability balances. Existing deferred rent and prepaid rent amounts were removed from the consolidated balance sheets at the date of adoption. The adoption did not have a material impact to the Company's consolidated statements of operations or statement of cash flows. The Company has made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. See Note 8 for further information. In December 2019, the FASB issued ASU No. 2019-12, I ncome Taxes-Simplifying the Accounting for Income Taxes

BUSINESS COMBINATION

BUSINESS COMBINATION	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATION	Business Combination As discussed in Note 1, on December 3, 2021, the Company consummated a business combination pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, THMA, who was the legal acquirer, was treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Pear issuing stock for the net assets of THMA, accompanied by a recapitalization. Upon the closing of the Business Combination, holders of Legacy Pear common stock received shares of Class A common stock in an amount determined by application of the exchange ratio of approximately 1.47 (the “ Exchange Ratio ”), which was based on Legacy Pear’s implied price per share prior to the Business Combination. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted (“ Retroactive Conversion ”) by applying the Exchange Ratio. The consolidated assets, liabilities and results of operations prior to the Business Combination are those of Legacy Pear. In addition, holders of Legacy Pear Common Shares (and Legacy Pear Preferred Shares who converted their shares into Legacy Pear Common Shares in connection with the Merger) received the contingent right to receive up to 12,395,625 additional shares of Class A common stock (the “Earn-Out Shares”) upon the achievement of certain earn-out targets. The holders of Legacy Pear common stock are eligible to receive up to 12,395,625 shares in the aggregate of additional shares of Class A common stock in three equal tranches of 4,131,875 shares respectively, upon the Company achieving $12.50, $15.00, or $17.50, respectively, as its volume-weighted average price per share for any 20 trading days within a 30 consecutive trading day period (as adjusted for share splits, reverse share splits, share dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares, or the like) during the period ending on December 3, 2026. Further, the Company assumed the outstanding warrants to purchase 9,199,944 shares of the Company’s Class A common stock at $11.50 per share (the “Public Warrants”) and the outstanding warrants (the “Private Placement Warrants”) held by LJ10 LLC, (the “ Sponsor ”) to purchase 5,013,333 shares of the Company’s Class A common stock at $11.50 per share. The Public Warrants and Private Placement Warrants expire five years after the completion of the Business Combination. In connection with the Business Combination, the Company incurred approximately $32,779 of equity issuance costs, consisting of underwriting, legal, and other professional fees, $31,400 of which were recorded to additional paid-in capital as a reduction of proceeds and $1,379 of which was recorded as an expense in selling, general, and administrative expenses on the consolidated statement of comprehensive income. See Note 7 for information on the Legacy Pear warrants that were exercised prior to the Business Combination. The number of shares of common stock outstanding immediately following the consummation of the business combination was as follows: Class A THMA Public Shares 832,899 THMA Initial Stockholders 6,900,000 Shares Issued pursuant to Forward Purchase Agreement to Anchor Investor 6,387,026 Shares Issued to PIPE Investors and Forward Purchase Assignment 10,280,000 Legacy Pear Equityholders (1) 113,399,293 Total shares of common stock immediately after business combination 137,799,218 (1) The number of Legacy Pear shares was determined from the shares of Legacy Pear shares outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio of approximately 1.47. All fractional shares were rounded down. Public Warrants and Private Placement Warrants As of the Closing Date, the total value of the liability associated with the Public and Private Placement Warrants was $16,487 measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability and have been classified as such on the balance sheet. The fair value of the warrant liability was $1,795 and $8,528 at June 30, 2022 and December 31, 2021, respectively. See Notes 4 and 11 for further information on the Public and Private Placement Warrants. Earn-Out Liabilities

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The tables below present certain of our assets and liabilities measured at fair value categorized by the level of input used in the valuation of each asset and liability. June 30, 2022 Description Total Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 17,239 $ 17,239 $ — $ — Commercial Paper 3,998 — 3,998 — Total cash equivalents 21,237 17,239 3,998 — Debt investments: U.S. Treasury Bills 20,975 20,975 — — Corporate bonds 10,989 — 10,989 — Commercial paper 14,958 — 14,958 — Total debt investments 46,922 20,975 25,947 — Total assets $ 68,159 $ 38,214 $ 29,945 $ — Long-term liabilities: Embedded debt derivative $ 123 $ — $ — $ 123 Warrant liabilities 1,795 1,162 633 — Earn-out liabilities 4,573 — — 4,573 Total liabilities $ 6,491 $ 1,162 $ 633 $ 4,696 December 31, 2021 Description Total Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 129,184 $ 129,184 $ — $ — Debt investments: Corporate bonds 1,007 — 1,007 — Commercial paper 3,998 — 3,998 — Total debt investments 5,005 — 5,005 — Total assets $ 134,189 $ 129,184 $ 5,005 $ — Long-term liabilities: Embedded debt derivative $ 675 $ — $ — $ 675 Warrant liabilities 8,528 5,520 3,008 Earn-out liabilities 48,363 — — 48,363 Total liabilities $ 57,566 $ 5,520 $ 3,008 $ 49,038 The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the three and six months ended June 30, 2022 and 2021. Cash equivalents —Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Investments —The Company measures its investments at fair value on a recurring basis and classifies those instruments within Level 1 and Level 2 of the fair value hierarchy. U.S. Treasury Bills are classified within Level 1 of the fair value hierarchy because pricing is based on quoted market prices for identical instruments in active markets of the reporting date. Marketable securities, including corporate bonds and commercial paper, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies. The Company recorded an unrealized loss of $77 and an unrealized gain of $1 for the three months ended June 30, 2022 and 2021, respectively, and an unrealized loss of $119 and an unrealized gain of $1 for the six months ended June 30, 2022 and 2021, respectively, in other comprehensive income (loss) on short-term investments. Embedded debt derivative — As described in Note 7, the Company concluded that the contingent put options contained in the Perceptive Credit Facility that could require mandatory repayment upon the occurrence of an event of default, change of control and certain other events represent an embedded derivative required to be bifurcated from the debt host instrument. The embedded debt derivative is measured at fair value using a probability-weighted cash flow valuation methodology, having a fair value of $123 at June 30, 2022. The change in estimated fair value of the embedded derivative resulted in a gain of $552 for the three and six months ended June 30, 2022, which is recorded in Interest and other (expense) income in the consolidated statement of operations and comprehensive income (loss). The determination of the fair value of an embedded debt derivative includes inputs not observable in the market and as such, represents a Level 3 measurement. The methodology utilized requires inputs based on certain subjective assumptions, specifically, probabilities of mandatory debt repayment prior to maturity ranging between 0 -10%. Warrant liabilities — A s a result of the Business Combination on December 3, 2021, the Company recorded a liability for Public and Private Placement Warrants to purchase Class A common stock in the Company’s consolidated financial statements. See Note 3 for further information. The Public Warrants are traded on Nasdaq and are recorded at fair value using the closing stock price as of the measurement date. The Private Placement Warrants, which have a single holder, have similar terms and are subject to substantially the same redemption features as the Public Warrants. Accordingly, the most advantageous market for the Private Placement Warrants is determined from the perspective of the holder of such warrants as an asset. Since any transfer to a non-permitted transferee (i.e., to a market participant) would cause the Private Placement Warrants to become public warrants, the fair value of the Private Placement Warrants is based on the quoted price of the Public Warrants. As of the Closing Date, the total value of the liability associated with the Public and Private Placement Warrants was $16,487 measured at fair value based on the public warrant quoted price on Nasdaq (Ticker: PEARW). The Company concluded that the warrants met the definition of a liability and have been classified as such on the balance sheet. At June 30, 2022, the fair value of the warrant liability was $1,795. Earn-out liabilities — Upon the closing of the Business Combination, the Earn-Out Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were indexed to the common stock of the Company, with the change fair value recognized in Change in the estimated fair value of earn-out liabilities in the consolidated statement of operations and comprehensive income (loss). The estimated fair value of the Earn-out Shares was determined using a Monte Carlo Simulation Method (“MCSM”) using the following assumptions at each valuation date: June 30, 2022 December 31, 2021 Stock price $1.54 $6.20 Risk-free interest rate 2.98% 1.25% Expected term (in years) 4.43 4.92 Expected volatility 65.80% 55.00% Dividend yield —% —% Refer to Note 3 for more information on the triggering events of the Earn-Out Shares. The change in fair value of the earn-out liabilities resulted in other income of $43,790 recognized in the consolidated statement of operations and comprehensive income (loss) for the six months ended June 30, 2022. The following table reconciles the change in the fair value of the earn-out liabilities valued using Level 3 inputs: Earn-Out Liabilities Fair value as of December 31, 2021 $ 48,363 Change in fair value (43,790) Fair value as of June 30, 2022 $ 4,573

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: June 30, 2022 December 31, 2021 Internal-use software $ 8,384 $ 6,591 Equipment 692 579 Construction in process — 362 Furniture and fixtures 711 586 Leasehold improvements 767 509 Total property and equipment 10,554 8,627 Less: accumulated depreciation (3,912) (2,372) Property and equipment, net $ 6,642 $ 6,255

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: June 30, 2022 December 31, 2021 Compensation and related benefits $ 10,063 $ 11,855 Commercial and marketing related costs 849 1,821 Professional services 1,161 1,710 Research and development costs 1,707 781 Other 1,291 1,779 Total $ 15,071 $ 17,946

INDEBTEDNESS

INDEBTEDNESS	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
INDEBTEDNESS	INDEBTEDNESS Perceptive Credit Facility On June 30, 2020, the Perceptive Close Date, the Company entered into a Credit Agreement and Guaranty, or Perceptive Credit Facility, with Perceptive Credit Holdings III, LP, as administrative agent and lender with a syndicate of other lenders, collectively Perceptive. The Perceptive Credit Facility, as amended, consists of a secured term loan facility in an aggregate amount of up to $50,000, which will be made available under the following three tranches: (i) Tranche 1 - $30,000, available at the Perceptive Closing Date; (ii) Tranche 2 - $10,000, available no later than December 31, 2021; and (iii) Tranche 3 - $10,000, available no later than December 31, 2021. The Company did not draw down on the available borrowings under Tranche 2 or Tranche 3. The Perceptive Credit Facility bears interest through maturity at a variable rate based upon the one-month LIBOR rate plus 11.0%, subject to a LIBOR floor of 1.0%. As of June 30, 2022, the interest rate was 12.1%. The Company is required to make interest-only payments until May 31, 2024, after which point the Company will be required to make monthly payments of principal equal to 3.0% of the then outstanding principal until maturity on June 30, 2025, or the Maturity Date. If the Company prepays the loan prior to the Maturity Date, it will be required to pay a prepayment fee guaranteeing Perceptive a 1.5 times return on any prepaid amount. A change of control, which includes a new entity or group owning more than 35.0% of the Company’s voting stock, or prior to an IPO, the failure of the existing holders to own at least 35.0% of the Company’s voting stock, trigger a mandatory prepayment of the term loan. The Business Combination did not trigger this clause as existing holders retained greater than 35% of the combined Company’s voting stock. The Company paid issuance costs of $750 in connection with its entry into the Perceptive Credit Facility. The Company concluded the contingent put options that could require mandatory repayment upon the occurrence of an event of default, change of control and certain other events represent an embedded derivative required to be bifurcated from the debt host instrument and accounted for separately and recorded an embedded debt derivative of $123 as of June 30, 2022 and $675 as of December 31, 2021. Any changes to the derivative liability in future periods will be recognized as interest and other (expense) income, net in the consolidated statements of operations and comprehensive loss. The Perceptive Credit Facility is secured by substantially all the assets of the Company, including our intellectual property. The Credit Facility requires the Company to (i) maintain a minimum aggregate cash balance of $5,000 in one or more controlled accounts, and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending March 31, 2022, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Facility which range from $5,750 for the fiscal quarter ending March 31, 2022, to $125,000 for the fiscal quarter ending March 31, 2025. The Perceptive Credit Facility contains various affirmative and negative covenants that limit the Company’s ability to engage in specified types of transactions. The Company was in compliance with the covenants under the Perceptive Credit Facility as of June 30, 2022. On the Perceptive Closing Date, Perceptive received a warrant certificate exercisable into 775,000 shares of Legacy Pear Series C preferred stock, and had the Company borrowed under Tranche 2 or Tranche 3, the Company would have been obligated to issue two additional warrants, the Additional Warrants, to Perceptive each to purchase up to 50,000 shares of Legacy Pear Series C preferred stock. In the event the Company issued Legacy Pear Series D preferred stock, Perceptive had the right to convert the Legacy Pear Series C preferred stock warrant into a warrant to purchase Legacy Pear Series D preferred stock, and the exercise price shall be automatically adjusted to equal the original per share price for Legacy Pear Series D preferred stock. On the Perceptive Closing Date, the Company issued freestanding Legacy Pear Series C preferred stock warrants to Perceptive, which were converted to Legacy Pear Series D preferred stock warrants at the time of the Legacy Pear Series D funding round. The Legacy Pear Series D preferred stock warrants were exercisable for 1,012,672 shares of Legacy Pear Series D preferred stock. The Legacy Pear Series D preferred stock warrants have an exercise price of $5.51 per share and would have expired in 2030 and were exercisable at any time prior to the ten-year anniversary of the Perceptive Closing Date of the Perceptive Credit Facility. At issuance, the Company determined that the warrant is liability-classified and would be remeasured at fair value each reporting period, with changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The Additional Warrants would have been issued as warrants to purchase 65,333 shares of Legacy Pear Series D-1 preferred stock. On November 30, 2021, Perceptive net exercised 1,012,672 Legacy Pear Series D warrants pursuant to which Perceptive obtained 629,057 shares of Legacy Pear Series D-1 preferred stock in a cashless exercise, and subsequently converted the 629,057 shares of Legacy Pear Series D-1 preferred stock into 629,057 shares of Legacy Pear common stock which were then converted into 926,232 shares of Class A common stock as adjusted by the exchange ratio based on a per share price of $9.87 per share, the THMA closing price on June 22, 2021. See Notes 1 and 3 for more information. On March 25, 2022, we amended the Perceptive Credit Facility to adjust certain covenants under the agreement. The amendment included among other things, reducing the required minimum trailing 12-month revenue for the fiscal quarter ending March 31, 2022, through the fiscal quarter ending March 31, 2025 as described above. On the Perceptive Closing Date, the Company received proceeds of $28,500, net of fees and expenses of $1,500. As of June 30, 2022, no further borrowings were taken under the Credit Facility. The outstanding balance of the Perceptive Credit Facility was: Perceptive Credit Facility June 30, 2022 Principal $ 30,000 Less: Debt issuance costs and discount at issuance (2,646) Net carrying amount $ 27,354 As discussed in Note 1, due to the substantial doubt about the Company’s ability to continue operating as a going concern for twelve months from the issuance date of these financial statements, the amounts due as of June 30, 2022, have been classified as current in the consolidated balance sheet. Future minimum payments, including contractual interest, under the Perceptive Credit Facility as of June 30, 2022, are as follows: Years ended December 31, Amounts Remainder of 2022 1,840 2023 3,650 2024 10,603 2025 24,039 Total $ 40,132 Less: Interest payable (10,132) Unamortized debt issuance costs (2,646) Current portion of long-term debt (27,354) Long-term debt $ —

LEASES

LEASES	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lessee, Operating Leases	LEASES As of June 30, 2022, the Company leases office space under non-cancelable operating leases in three cities, Boston, Massachusetts, consisting of approximately 19,000 square feet that will expire on June 1, 2028, including approximately 900 square feet that the Company took over on January 1, 2022, San Francisco, California, consisting of approximately 17,000 square feet that will expire on July 31, 2025, and Raleigh, North Carolina, consisting of approximately 7,700 square feet that will expire on May 31, 2026. We have the right and option to extend each of the Boston and Raleigh leases for a five year period. As described in Note 2, the Company adopted Topic 842, Leases , as of January 1, 2022. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840. All of the Company's leases are classified as operating leases. The components of ROU assets and lease liabilities are included in the condensed consolidated balance sheets. We recognized rent expense of $713 and $1,454 for the three and six months ended June 30, 2022, respectively, and $733 and $1,376 for the three and six months ended June 30, 2021, respectively. The Company had $1,007 in deferred rent recorded within other long-term liabilities in the consolidated balance sheet as of December 31, 2021. Future commitments under non-cancelable lease agreements are as follows: Years ended December 31, Lease Commitments Remainder of 2022 $ 1,412 2023 2,912 2024 3,176 2025 2,734 2026 and thereafter 3,878 Total lease payments 14,112 Less: present value adjustment (3,074) Present value of total lease liabilities 11,038 Less: current lease liability (1,821) Long-term operating lease liabilities $ 9,217 As of December 31, 2021, prior to the adoption of ASC 842, the estimated minimum future lease payments for the next five years and thereafter was as follows: Years ended December 31, Lease Commitments 2022 2,809 2023 2,912 2024 3,176 2025 2,734 2026 and thereafter 3,879 Total 15,510 Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities. As of June 30, 2022, the weighted average remaining lease term is 4.9 years and the weighted average discount rate used to determine the operating lease liability is 10%. In addition to rent, certain leases require the Company to pay additional amounts for taxes, insurance, maintenance, and other operating expenses.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Licenses Related to our Commercial Products As of June 30, 2022, the Company has four license agreements related to its commercialized products. The Invention Science Fund I, LLC The Company entered into a contribution and license agreement for Pharmaceutical Field of Use, or FOU, with The Invention Science Fund I, LLC, or ISF, in February 2015, as amended on February 28, 2018, or ISF Contribution and License Agreement. The ISF Contribution and License Agreement superseded an original contribution and license agreement between the Company and ISF dated December 31, 2013. Under the ISF Contribution and License Agreement, ISF granted the Company certain licenses under specified patent rights to develop and commercialize licensed products either independently and/or with a drug combination product for use in connection with the treatment of central nervous system disorders. The ISF Contribution and License Agreement contains minimum annual royalty obligations. To the extent there are sales of a licensed product, the Company is required to pay low-single-digit royalties on net revenue. The Company recorded minimum annual royalty fees of $250 and $500 to ISF for the three and six months ended June 30, 2022, respectively, and $250 and $500 for the three and six months ended June 30, 2021, respectively. Red 5 Group, LLC In January 2015, the Company entered into a software license agreement with Red 5 Group, LLC, or Red 5, and in March 2018, the parties entered into an amended and restated software license agreement, or Amended Red 5 Group License. Under the original software license agreement, Red 5 licensed the Company certain technology and materials relating to the treatment of psychological and substance use disorders, pursuant to which the Company, received, inter alia, an exclusive, worldwide, sublicensable, royalty-bearing license to develop and commercialize integrated products incorporating the licensed technology and materials. The Company agreed to use commercially reasonable efforts to develop integrated products in accordance with the development plan, to introduce any integrated products that gain regulatory approval into the commercial markets, to market integrated products that have gained regulatory approval following such introduction into the market, and to make integrated products that have gained regulatory approval reasonably available to the public. In March 2018, pursuant to the Amended Red 5 Group License, the parties expanded the scope of exclusivity of the license, increased certain specified annual license maintenance fees, and required the Company to pay Red 5 an amendment fee, which was paid in April 2018. On July 1, 2021, the parties amended the Amended Red 5 Group License to further clarify certain terms and increase the royalty rate by a de minimis amount. To the extent achieved, the Company is obligated to pay up to an aggregate of $400 if certain milestones related to product regulatory approval and commercial sales are achieved in respect to a software/drug combination, which is not currently being pursued by the Company. To the extent there are sales of an integrated product, the Company is required to pay single-digit royalties on net revenues. The Company is entitled to certain reductions and offsets against its royalty and milestone payment obligations, including the annual license maintenance fees. On July 1, 2021, the parties amended the Amended Red 5 License Agreement to further clarify certain terms and increase the royalty rate by a de minimis amount. The Company pays minimum annual maintenance fees to Red 5 in connection with reSET and reSET-O. The Company recorded minimum annual maintenance fees of $62 and $125 to Red 5 for the three and six months ended June 30, 2022, respectively, and $62 and $125 for the three and six months ended June 30, 2021, respectively. BeHealth Solutions, LLC and University of Virginia Patent Foundation In March 2018, the Company and BeHealth Solutions, LLC, or BeHealth, entered into an assignment, license and services agreement, or the BeHealth Agreement, as well as a consulting agreement. The BeHealth Agreement closed in June 2018 and the Company paid an up-front fee. Under the BeHealth Agreement, the Company obtained license rights to certain technology and materials relating to a therapeutic treatment for insomnia. The consulting agreement is for services to be charged on a time-and-materials basis. During the year ended December 31, 2020, the Company paid a milestone payment to BeHealth of $750 upon the FDA’s marketing authorization of Somryst, a PDT intended for use in the treatment of adults with chronic insomnia. During September 2021, a commercial milestone under the license agreement with BeHealth was achieved and the Company paid $1,000 during the year ended December 31, 2021. The milestone payments are capitalized in other long-term assets in the accompanying consolidated balance sheets and amortized on a straight-line basis to cost of product revenue over the estimated useful life of five years. The BeHealth Agreement continues in force until the expiration of all milestone and royalty payment obligations, unless terminated earlier in accordance with its terms. The Company could be obligated to make payments of up to an additional $26,000 in the aggregate upon achievement of various commercial milestones and a mid-to-high-single-digit royalty on net sales. The Company pays royalties based on net revenues of the sales of Somryst to BeHealth and the University of Virginia Patent Foundation, or UVPF. The Company recorded de minimis royalties to BeHealth and UVPF for the three and six months ended June 30, 2022 and 2021. Guarantees and Indemnifications As permitted under Delaware law, the Company indemnifies its officers, directors and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. In addition, the indemnification agreements entered into with our former board members, Messrs. Schwab and Lynch, also provide certain indemnification rights to the entities with which they are affiliated. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. Further, the Company is a party to a variety of agreements in the ordinary course of business under which it may be obligated to indemnify third parties with respect to certain matters. For the three and six months ended June 30, 2022 and 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding as of June 30, 2022. The Company does not expect significant claims related to these indemnification obligations and consequently concluded that the fair value of these obligations is negligible and no related accruals were recorded. Purchase Commitment On June 17, 2021, and later amended on August 3, 2021, the Company entered into a non-cancelable purchase obligation for a subscription to the Palantir Foundry cloud platform , including support services, updates, and related professional services with Palantir for $9,300 payable over three years, continuing through September 30, 2024. Through June 30, 2022, the Company recorded $2,983 under the terms of the agreement, $2,331 of which is included in prepaid expenses on the consolidated balance sheet as of June 30, 2022. Assignment and License Agreement In November 2021, the Company and Waypoint Health Innovations, LLC (“Waypoint”) entered into an Assignment Agreement and Intellectual Property License Agreement (collectively, the “Waypoint Agreement”). The Waypoint Agreement closed in December 2021, under which the Company obtained software, documentation, and other intellectual property rights relating to the therapeutic treatment of depression. At the same time, the Company entered into a consulting agreement with the Chief Executive Officer of Waypoint to provide certain services to Pear to be charged on a time-and-materials basis. The Company made an upfront payment of $1,350, and is required to make annual payments starting in the second half of 2022 of $250 per year through 2026 or until a commercial milestone payment is made under the agreement. The upfront payment and the net present value of the annual payments of $1,011 were capitalized and recorded as an intangible asset in consolidated balance sheet at closing, and are being amortized over five years. The net present value of the annual payments was recognized as a seller financing liability, and classified within accrued expenses and other current liabilities and other long-term liabilities on the balance sheet. The Company will be obligated to pay mid-single digit royalties on net revenues of any commercialized products that incorporate the assets obtained under the Waypoint Agreement. Additionally, the Company could be obligated to make payments of up to an additional $2,500 in the aggregate upon achievement of certain regulatory and commercial milestones. Through June 30, 2022, no royalties have been paid to Waypoint. Legal Proceedings The Company is also involved from time to time in various legal proceedings arising in the normal course of business. Although the outcomes of potential legal proceedings are inherently difficult to predict, the Company

REVENUE AND CONTRACT BALANCES

REVENUE AND CONTRACT BALANCES	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
REVENUE AND CONTRACT BALANCES	REVENUE AND CONTRACT BALANCES Contract Balances We enter into agreements with health care providers and payors, and state and local governments, to provide prescriptions which provide for volume-based discounts and other discounts, and in certain circumstances, value-based rebates (“Access Agreements”). We also enter into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates and discounts with respect to the purchase of our products. A portion of the product revenue is recognized when the products are made available to the customer (via Access Agreements) or when a prescription is fulfilled (via third party reimbursement), and the portion of the product revenue related to the clinician’s access to our proprietary clinician dashboard is deferred and recognized ratably over the remaining term of the contract (if purchased via an Access Agreement) or the prescription duration (if purchased via third party reimbursement). The timing of revenue recognition, invoicing, and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoice our Access Agreement customers in accordance with agreed-upon contractual terms, typically at the beginning of the agreement, or at periodic intervals throughout the contract term. Invoicing may occur subsequent to revenue recognition, resulting in unbilled receivables, or in advance of services being provided, resulting in deferred revenue. Deferred revenue that will be recognized during the twelve-month period from the balance sheet date is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue, which is included in Other long-term liabilities in the accompanying consolidated balance sheets. The following table summarizes the balances of our contract assets and liabilities: June 30, 2022 December 31, 2021 Contract assets Accounts receivables $ 490 $ 555 Unbilled receivables 4,489 1,239 Contract liabilities Deferred revenue - current 680 421 Deferred revenue - non-current 26 22 During the six months ended June 30, 2022, the Company recognized revenue of approximately $271 that was included in deferred revenue at December 31, 2021. Collaboration Arrangements

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
CAPITAL STOCK	CAPITAL STOCK The Company’s authorized capital stock consists of (a) 690,000,000 shares of common stock, par value $0.0001 per share; and (b) 10,000,000 shares of preferred stock, par value $0.0001 per share. As of June 30, 2022, there were 138,677,770 shares of Class A common stock issued and outstanding and 14,213,267 Warrants to purchase the Company’s Class A common stock outstanding. As of June 30, 2022, there were no shares of preferred stock issued or outstanding.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION AND BENEFIT PLANS The Company incurred stock-based compensation expenses of $3,386 and $6,287 for the three and six months ended June 30, 2022, respectively, and $572 and $1,035 for the three and six months ended June 30, 2021, respectively. Stock Incentive Plans On December 20, 2013, Legacy Pear’s board of directors adopted the 2013 Stock Incentive Plan, or the 2013 Plan, which provided for the grant of stock options, both incentive stock options and nonqualified stock options and restricted stock, to be granted to officers, directors, consultants, and service providers. As last amended and approved by the board of directors on November 3, 2020, the Company was permitted to grant up to 16,727,451 incentive awards under the 2013 Plan. In connection with the closing of the Business Combination, the Company adopted the 2021 Incentive Award Plan (the “ 2021 Plan ”) a shareholder-approved plan that provides for broad-based equity grants to employees and certain non-employees, including executive officers and permits the granting of restricted stock units (“ RSUs ”), stock grants, performance based awards, stock options and stock appreciation rights, as well as cash bonus awards. All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s consolidated statement of operations and comprehensive income (loss) over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period). RSUs granted under the 2021 Plan generally vest over three years, based on continued employment, and are settled upon vesting in shares of the Company’s Class A common stock on a one-for-one basis. As of June 30, 2022, a total of 38,891,801 shares of Class A common stock are reserved under the Plan, including a total of 32,000,000 shares initially reserved for issuance under the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase each January 1, beginning on January 1, 2022 and ending in 2031, by 5% of the outstanding number of Class A common stock on the immediately preceding December 31, or such lesser amount as determined by the plan administrator (the Company’s board of directors or compensation committee). During the six months ended June 30, 2022 and 2021, the Company granted stock options to purchase 1,016,918 and 3,857,536 shares of common stock with aggregate grant date fair values of $2,536 and $2,743, respectively. Common Stock Options The combined stock option activity for the six months ended June 30, 2022, is as follows: Stock Options Weighted Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Options outstanding at December 31, 2021 19,381,975 $3.02 8.16 Granted 1,016,918 $4.14 Exercised (841,732) $0.99 Canceled and forfeited (1,206,632) $5.08 Options outstanding at June 30, 2022 18,350,529 $3.04 7.74 $ 6,493 Exercisable at June 30, 2022 8,684,822 $1.06 6.52 $ 5,220 The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2022 and 2021, was $2.49 and $1.34 per share, respectively. The fair value of stock options that vested during the six months ended June 30, 2022, was $2,169. As of June 30, 2022, the total unrecognized compensation costs related to non-vested stock options were approximately $23,582 and are expected to be recognized over a weighted average period of 2.95 years. Restricted Stock Units Restricted Stock Units (RSUs) generally vest in equal annual installments over a three year period. The grant-date fair value of the RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of restricted stock units based on the closing price of its common stock on the date of the grant. RSU activity is as follows: Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2021 — — Granted 5,092,531 $ 3.67 Forfeited and canceled (299,090) 4.06 Outstanding as of June 30, 2022 4,793,441 $ 3.64 As of June 30, 2022, there was $15,349 of unrecognized compensation cost related to time-based RSUs which is expected to be recognized over a weighted-average period of 2.43 years. Stock Compensation Expense The assumptions used to estimate the grant date fair value using the Black-Scholes option pricing model were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Risk-free interest rate n/a 1.09 % 1.86 % 0.84 % Expected volatility n/a 70.87 % 65.69 % 70.63 % Expected term (years) n/a 5.67-6.12 5.42-6.57 5.67-6.0 Expected dividend yield n/a — % — % — % There were no options granted during the three months ended June 30, 2022. The Company has classified stock-based compensation in its consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of product revenue $ 151 $ 7 $ 250 $ 13 Research and development 1,294 210 2,599 378 Selling, general, and administrative 1,941 355 3,438 644 Total stock-based compensation expense $ 3,386 $ 572 $ 6,287 $ 1,035 Employee Stock Purchase Plan In connection with the closing of the Business Combination, the Company adopted the 2021 Employee Stock Purchase Plan (the “ 2021 ESPP ”). The 2021 ESPP is a shareholder-approved plan under which substantially all employees may voluntarily enroll to purchase the Company’s common stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. An employee’s payroll deductions under the 2021 ESPP are limited to 15% of the employee’s compensation and employees may not purchase more than $25,000 of stock during any calendar year.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESDuring the three and six months ended June 30, 2022 and 2021, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	NET INCOME (LOSS) PER SHARE Potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. For periods in which the Company reports a net loss attributable to common stockholders, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Three and Six Months Ended June 30, 2021 Outstanding common stock options 5,821,333 18,350,529 14,880,420 Unvested restricted stock units 153,061 4,793,441 — Warrants to purchase Legacy Pear common stock — — 1,126,705 Private placement warrants to purchase common stock 5,013,333 5,013,333 — Public warrants to purchase common stock 9,199,934 9,199,934 — Earn-Out Shares 12,395,625 12,395,625 — Total 32,583,286 49,752,862 16,007,125 The following table summarizes the computation of basic net loss per share attributable to common stockholders of the Company for the three and six months ended June 30 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 5,462 $ (28,201) $ (18,397) $ (52,594) Denominator: Weighted-average common shares outstanding for basic net income (loss) per share (1) 138,288,357 111,946,894 138,071,377 110,311,459 Net income (loss) per share attributable to common stockholders, basic and diluted (1) $ 0.04 $ (0.25) $ (0.13) $ (0.48) (1) The weighted-average common shares and thus the net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Historically reported weighted average shares outstanding have been multiplied by the exchange ratio of approximately 1.47. See Note 3 for further information. A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 5,462 $ (28,201) $ (18,397) $ (52,594) Denominator: Weighted-average common shares outstanding (1) 138,288,357 111,946,894 138,071,377 110,311,459 Plus: incremental shares from assumed conversion 9,133,686 — — — Adjusted weighted average common shares outstanding 147,422,043 111,946,894 138,071,377 110,311,459 Diluted net income (loss) per share attributable to common stockholders (1) $ 0.04 $ (0.25) $ (0.13) $ (0.48)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 25, 2022, the Company restructured its operations to narrow its near-term business focus and reduce its workforce due to the macroeconomic environment. The Company's restructuring includes external and internal cost reductions in almost all areas of the Company. The Company focused cost reductions on pipeline candidates, discovery programs, business development, and the Company's dual platform in order to prioritize certain of its commercial efforts. The reduction in workforce will decrease overall headcount by approximately 25 employees, which represents approximately 9% of full-time employees of the then workforce. The Company expects to incur a one-time charge of approximately $0.9 million in the third quarter of 2022 related to the reduction in workforce, consisting primarily of one-time severance payments upon termination of the employees and continued benefits for a specific period of time with related cash payments expected to be substantially paid out by September 30, 2022. The Company expects such payments to be the only direct expense of the reduction in workforce. The Company does not expect to recognize a stock-based compensation expense for impacted employees related to vested awards and does not anticipate modifying the affected employees’ stock awards in a manner that would result in additional expenses. The severance-related and non-cash charges that the Company expects to incur in connection with, or as a result of, the workforce reduction, are subject to a number of assumptions, and actual results may differ. * * * * * *

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB. The consolidated financial statements as of June 30, 2022 and 2021, and for the three and six months ended June 30, 2022 and 2021, include the accounts of Pear and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements herein.
Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB. The consolidated financial statements as of June 30, 2022 and 2021, and for the three and six months ended June 30, 2022 and 2021, include the accounts of Pear and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements herein.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and various other assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates and changes in estimates are reflected in reported results in the period in which they become known.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers only those highly liquid investments, readily convertible to cash, that mature within 90 days from the date of purchase to be cash equivalents. The Company’s cash equivalents include money market funds, commercial paper, and overnight deposits.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842) , as subsequently amended, which provides guidance requiring lessees to recognize a right-of-use asset (“ ROU ”) and a lease liability on the balance sheet for substantially all leases, with the exception of short-term leases. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of operations. The Company adopted the leasing standard effective January 1, 2022, using the revised modified retrospective transition method, with comparative periods continuing to be reported under ASC 840 as it was the accounting standard in effect for such period. In the adoption of ASU 2016-02, the Company carried forward the assessment from ASC 840 of whether its contracts contain or are leases, the classification of its leases, and remaining lease terms. The Company did not elect the hindsight practical expedient upon adoption of the new standard. The most significant impact resulting from the adoption of this new standard was the recognition of ROU assets of $10,614 and operating lease liabilites of $11,860 on the adoption date, January 1, 2022. The difference between the ROU assets and lease liabilities on the accompanying condensed consolidated balance sheet is primarily due to the accrual for lease payments as a result of straight-line lease expense and unamortized tenant incentive liability balances. Existing deferred rent and prepaid rent amounts were removed from the consolidated balance sheets at the date of adoption. The adoption did not have a material impact to the Company's consolidated statements of operations or statement of cash flows. The Company has made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. See Note 8 for further information. In December 2019, the FASB issued ASU No. 2019-12, I ncome Taxes-Simplifying the Accounting for Income Taxes

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows: June 30, 2022 December 31, 2021 Reconciliation of cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 60,185 $ 169,567 Restricted cash - short-term 66 — Restricted cash - long-term 411 411 Total cash, cash equivalents, and restricted cash $ 60,662 $ 169,978
Schedule of Restricted Cash	The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows: June 30, 2022 December 31, 2021 Reconciliation of cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 60,185 $ 169,567 Restricted cash - short-term 66 — Restricted cash - long-term 411 411 Total cash, cash equivalents, and restricted cash $ 60,662 $ 169,978
Schedule of Property and Equipment	Property and equipment, net consists of the following: June 30, 2022 December 31, 2021 Internal-use software $ 8,384 $ 6,591 Equipment 692 579 Construction in process — 362 Furniture and fixtures 711 586 Leasehold improvements 767 509 Total property and equipment 10,554 8,627 Less: accumulated depreciation (3,912) (2,372) Property and equipment, net $ 6,642 $ 6,255

BUSINESS COMBINATION (Tables)

BUSINESS COMBINATION (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule Of Reverse Capitalization	The number of shares of common stock outstanding immediately following the consummation of the business combination was as follows: Class A THMA Public Shares 832,899 THMA Initial Stockholders 6,900,000 Shares Issued pursuant to Forward Purchase Agreement to Anchor Investor 6,387,026 Shares Issued to PIPE Investors and Forward Purchase Assignment 10,280,000 Legacy Pear Equityholders (1) 113,399,293 Total shares of common stock immediately after business combination 137,799,218 (1) The number of Legacy Pear shares was determined from the shares of Legacy Pear shares outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio of approximately 1.47. All fractional shares were rounded down.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities at Fair Value	The tables below present certain of our assets and liabilities measured at fair value categorized by the level of input used in the valuation of each asset and liability. June 30, 2022 Description Total Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 17,239 $ 17,239 $ — $ — Commercial Paper 3,998 — 3,998 — Total cash equivalents 21,237 17,239 3,998 — Debt investments: U.S. Treasury Bills 20,975 20,975 — — Corporate bonds 10,989 — 10,989 — Commercial paper 14,958 — 14,958 — Total debt investments 46,922 20,975 25,947 — Total assets $ 68,159 $ 38,214 $ 29,945 $ — Long-term liabilities: Embedded debt derivative $ 123 $ — $ — $ 123 Warrant liabilities 1,795 1,162 633 — Earn-out liabilities 4,573 — — 4,573 Total liabilities $ 6,491 $ 1,162 $ 633 $ 4,696 December 31, 2021 Description Total Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 129,184 $ 129,184 $ — $ — Debt investments: Corporate bonds 1,007 — 1,007 — Commercial paper 3,998 — 3,998 — Total debt investments 5,005 — 5,005 — Total assets $ 134,189 $ 129,184 $ 5,005 $ — Long-term liabilities: Embedded debt derivative $ 675 $ — $ — $ 675 Warrant liabilities 8,528 5,520 3,008 Earn-out liabilities 48,363 — — 48,363 Total liabilities $ 57,566 $ 5,520 $ 3,008 $ 49,038
Schedule of Valuation Assumptions	The estimated fair value of the Earn-out Shares was determined using a Monte Carlo Simulation Method (“MCSM”) using the following assumptions at each valuation date: June 30, 2022 December 31, 2021 Stock price $1.54 $6.20 Risk-free interest rate 2.98% 1.25% Expected term (in years) 4.43 4.92 Expected volatility 65.80% 55.00% Dividend yield —% —%
Summary of Changes in the Fair Value of Level 3 Liabilities	The following table reconciles the change in the fair value of the earn-out liabilities valued using Level 3 inputs: Earn-Out Liabilities Fair value as of December 31, 2021 $ 48,363 Change in fair value (43,790) Fair value as of June 30, 2022 $ 4,573

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following: June 30, 2022 December 31, 2021 Internal-use software $ 8,384 $ 6,591 Equipment 692 579 Construction in process — 362 Furniture and fixtures 711 586 Leasehold improvements 767 509 Total property and equipment 10,554 8,627 Less: accumulated depreciation (3,912) (2,372) Property and equipment, net $ 6,642 $ 6,255

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consist of the following: June 30, 2022 December 31, 2021 Compensation and related benefits $ 10,063 $ 11,855 Commercial and marketing related costs 849 1,821 Professional services 1,161 1,710 Research and development costs 1,707 781 Other 1,291 1,779 Total $ 15,071 $ 17,946

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long Term Debt	The outstanding balance of the Perceptive Credit Facility was: Perceptive Credit Facility June 30, 2022 Principal $ 30,000 Less: Debt issuance costs and discount at issuance (2,646) Net carrying amount $ 27,354
Schedule of Future Minimum Payments	Future minimum payments, including contractual interest, under the Perceptive Credit Facility as of June 30, 2022, are as follows: Years ended December 31, Amounts Remainder of 2022 1,840 2023 3,650 2024 10,603 2025 24,039 Total $ 40,132 Less: Interest payable (10,132) Unamortized debt issuance costs (2,646) Current portion of long-term debt (27,354) Long-term debt $ —

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of Lease Payments	Future commitments under non-cancelable lease agreements are as follows: Years ended December 31, Lease Commitments Remainder of 2022 $ 1,412 2023 2,912 2024 3,176 2025 2,734 2026 and thereafter 3,878 Total lease payments 14,112 Less: present value adjustment (3,074) Present value of total lease liabilities 11,038 Less: current lease liability (1,821) Long-term operating lease liabilities $ 9,217
Schedule of Lease Payments	As of December 31, 2021, prior to the adoption of ASC 842, the estimated minimum future lease payments for the next five years and thereafter was as follows: Years ended December 31, Lease Commitments 2022 2,809 2023 2,912 2024 3,176 2025 2,734 2026 and thereafter 3,879 Total 15,510

REVENUE AND CONTRACT BALANCES (

REVENUE AND CONTRACT BALANCES (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Contract assets and liabilities	The following table summarizes the balances of our contract assets and liabilities: June 30, 2022 December 31, 2021 Contract assets Accounts receivables $ 490 $ 555 Unbilled receivables 4,489 1,239 Contract liabilities Deferred revenue - current 680 421 Deferred revenue - non-current 26 22

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The combined stock option activity for the six months ended June 30, 2022, is as follows: Stock Options Weighted Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Options outstanding at December 31, 2021 19,381,975 $3.02 8.16 Granted 1,016,918 $4.14 Exercised (841,732) $0.99 Canceled and forfeited (1,206,632) $5.08 Options outstanding at June 30, 2022 18,350,529 $3.04 7.74 $ 6,493 Exercisable at June 30, 2022 8,684,822 $1.06 6.52 $ 5,220
Schedule of RSU Activity	RSU activity is as follows: Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2021 — — Granted 5,092,531 $ 3.67 Forfeited and canceled (299,090) 4.06 Outstanding as of June 30, 2022 4,793,441 $ 3.64
Schedule of Valuation Assumptions	The assumptions used to estimate the grant date fair value using the Black-Scholes option pricing model were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Risk-free interest rate n/a 1.09 % 1.86 % 0.84 % Expected volatility n/a 70.87 % 65.69 % 70.63 % Expected term (years) n/a 5.67-6.12 5.42-6.57 5.67-6.0 Expected dividend yield n/a — % — % — %
Schedule of Stock Based Compensation Expense	The Company has classified stock-based compensation in its consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of product revenue $ 151 $ 7 $ 250 $ 13 Research and development 1,294 210 2,599 378 Selling, general, and administrative 1,941 355 3,438 644 Total stock-based compensation expense $ 3,386 $ 572 $ 6,287 $ 1,035

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities	The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Three and Six Months Ended June 30, 2021 Outstanding common stock options 5,821,333 18,350,529 14,880,420 Unvested restricted stock units 153,061 4,793,441 — Warrants to purchase Legacy Pear common stock — — 1,126,705 Private placement warrants to purchase common stock 5,013,333 5,013,333 — Public warrants to purchase common stock 9,199,934 9,199,934 — Earn-Out Shares 12,395,625 12,395,625 — Total 32,583,286 49,752,862 16,007,125
Schedule of Net Loss Per Share	The following table summarizes the computation of basic net loss per share attributable to common stockholders of the Company for the three and six months ended June 30 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 5,462 $ (28,201) $ (18,397) $ (52,594) Denominator: Weighted-average common shares outstanding for basic net income (loss) per share (1) 138,288,357 111,946,894 138,071,377 110,311,459 Net income (loss) per share attributable to common stockholders, basic and diluted (1) $ 0.04 $ (0.25) $ (0.13) $ (0.48) (1) The weighted-average common shares and thus the net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Historically reported weighted average shares outstanding have been multiplied by the exchange ratio of approximately 1.47. See Note 3 for further information. A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 5,462 $ (28,201) $ (18,397) $ (52,594) Denominator: Weighted-average common shares outstanding (1) 138,288,357 111,946,894 138,071,377 110,311,459 Plus: incremental shares from assumed conversion 9,133,686 — — — Adjusted weighted average common shares outstanding 147,422,043 111,946,894 138,071,377 110,311,459 Diluted net income (loss) per share attributable to common stockholders (1) $ 0.04 $ (0.25) $ (0.13) $ (0.48)

NATURE OF BUSINESS - Organizati

NATURE OF BUSINESS - Organization (Details) $ / shares in Units, $ in Thousands		6 Months Ended
	Dec. 03, 2021 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares	Dec. 31, 2021 $ / shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
PIPE investment | $		$ 102,800
Transaction costs | $	$ 32,779
Gross proceeds | $		$ 175,001
Class A Common Stock
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Exchange ratio	1.47
Conversion ratio | shares	1
Issuance of common stock in connection with Business Combination and PIPE offering (in shares) | shares	832,899
Class A Common Stock | Anchor Investor
Subsidiary, Sale of Stock [Line Items]
Sale of stock (in shares) | shares	6,387,026
Sale of stock (in dollars per share) | $ / shares	$ 10
Class A Common Stock | Private Placement
Subsidiary, Sale of Stock [Line Items]
Sale of stock (in shares) | shares	10,280,000
Sale of stock (in dollars per share) | $ / shares	$ 10

NATURE OF BUSINESS - Narrative

NATURE OF BUSINESS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (5,462)	$ 23,859	$ 28,201	$ 24,393	$ 18,397	$ 52,594
Accumulated deficit	266,380				266,380		$ 247,983
Cash and cash equivalents and short-term investments	$ 107,107				$ 107,107

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 60,185	$ 169,567
Restricted cash - short-term	66	0
Restricted cash - long-term	411	411
Total cash, cash equivalents, and restricted cash	$ 60,662	$ 169,978	$ 93,380	$ 112,061

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROUs	$ 9,768		$ 0
Lease liabilities	$ 11,038
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROUs		$ 10,614
Lease liabilities		$ 11,860

BUSINESS COMBINATION (Details)

BUSINESS COMBINATION (Details) $ / shares in Units, $ in Thousands	Dec. 03, 2021 USD ($) Tranche Day $ / shares shares	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Earn-out liabilities	$ 95,401	$ 4,573	$ 48,363
Transaction costs	$ 32,779
Thimble Point Acquisition Corp.
Business Acquisition [Line Items]
Shares issuable (in shares) | shares	12,395,625
Number of tranches | Tranche	3
Threshold trading days | Day	20
Consecutive trading days | Day	30
Additional Paid-In Capital
Business Acquisition [Line Items]
Transaction costs	$ (31,400)
Selling, general, and administrative
Business Acquisition [Line Items]
Transaction costs	$ (1,379)
Tranche One | Thimble Point Acquisition Corp.
Business Acquisition [Line Items]
Price per share (in dollars per share) | $ / shares	$ 12.50
Tranche Two | Thimble Point Acquisition Corp.
Business Acquisition [Line Items]
Price per share (in dollars per share) | $ / shares	15
Tranche Three | Thimble Point Acquisition Corp.
Business Acquisition [Line Items]
Price per share (in dollars per share) | $ / shares	$ 17.50
Class A Common Stock
Business Acquisition [Line Items]
Exchange ratio	1.47
Class A Common Stock | Thimble Point Acquisition Corp.
Business Acquisition [Line Items]
Shares issuable (in shares) | shares	4,131,875

BUSINESS COMBINATION - Schedule

BUSINESS COMBINATION - Schedule of Reverse Capitalization (Details) - shares	Jun. 30, 2022	Dec. 31, 2021	Dec. 03, 2021
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)	138,677,770	137,836,028
Class A Common Stock
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			137,799,218
Class A Common Stock | THMA Public
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			832,899
Class A Common Stock | THMA Initial Stockholders
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			6,900,000
Class A Common Stock | Forward Purchase Agreement To Anchor Investor
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			6,387,026
Class A Common Stock | PIPE Investors And Forward Purchase Agreement
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			10,280,000
Class A Common Stock | Legacy Pear Equityholders
Schedule Of Reverse Recapitalization [Line Items]
Common stock, outstanding (in shares)			113,399,293

BUSINESS COMBINATION - Warrants

BUSINESS COMBINATION - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 03, 2021
Business Acquisition [Line Items]
Warrants outstanding (in shares)	14,213,267
Warrant liabilities	$ 1,795	$ 8,528
Public And Private Placement Warrants
Business Acquisition [Line Items]
Warrant liabilities			$ 16,487
Public warrants to purchase common stock
Business Acquisition [Line Items]
Warrants outstanding (in shares)	9,199,944
Exercise price (in dollars per share)	$ 11.50
Private placement warrants to purchase common stock
Business Acquisition [Line Items]
Warrants outstanding (in shares)	5,013,333
Exercise price (in dollars per share)	$ 11.50
Expiration period	5 years

FAIR VALUE MEASUREMENTS - Asset

FAIR VALUE MEASUREMENTS - Assets and Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 03, 2021	Jun. 30, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	$ 21,237
Debt investments	46,922	$ 5,005
Total assets	68,159	134,189
Embedded debt derivative	123	675		$ 123
Warrant liabilities	1,795	8,528
Earn-out liabilities	4,573	48,363	$ 95,401
Total liabilities	6,491	57,566
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	17,239
Debt investments	20,975	0
Total assets	38,214	129,184
Embedded debt derivative	0	0
Warrant liabilities	1,162	5,520
Earn-out liabilities	0	0
Total liabilities	1,162	5,520
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	3,998
Debt investments	25,947	5,005
Total assets	29,945	5,005
Embedded debt derivative	0	0
Warrant liabilities	633	3,008
Earn-out liabilities	0	0
Total liabilities	633	3,008
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	0
Debt investments	0	0
Total assets	0	0
Embedded debt derivative	123	675
Warrant liabilities	0
Earn-out liabilities	4,573	48,363
Total liabilities	4,696	49,038
U.S. Treasury Bills
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	20,975
U.S. Treasury Bills | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	20,975
U.S. Treasury Bills | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0
U.S. Treasury Bills | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0
Corporate bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	10,989	1,007
Corporate bonds | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0	0
Corporate bonds | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	10,989	1,007
Corporate bonds | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0	0
Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	14,958	3,998
Commercial paper | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0	0
Commercial paper | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	14,958	3,998
Commercial paper | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt investments	0	0
Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	17,239	129,184
Money market funds | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	17,239	129,184
Money market funds | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	0	0
Money market funds | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	0	$ 0
Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	3,998
Commercial paper | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	0
Commercial paper | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	3,998
Commercial paper | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash Equivalents	$ 0

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 03, 2021 USD ($)
Fair Value Disclosures [Abstract]
Unrealized gain (loss) on short-term investments	$ (77)	$ 1	$ (119)	$ 1
Embedded debt derivative	123	123	123	123	$ 675
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities	1,795		1,795		$ 8,528
Change in estimated fair value of earn-out liabilities	29,163	$ 0	43,790	$ 0
Gain on embedded derivative	$ 552		$ 552
Public And Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liabilities						$ 16,487
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt measurement input	0		0
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt measurement input	0.10		0.10

FAIR VALUE MEASUREMENTS - Valua

FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)	Jun. 30, 2022 year	Dec. 31, 2021 year
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability	1.54	6.20
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability	0.0298	0.0125
Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability	4,430	4,920
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability	0.6580	0.5500
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability	0	0

FAIR VALUE MEASUREMENTS - Level

FAIR VALUE MEASUREMENTS - Level 3 Roll Forward (Details) - Earn-out Liabilities $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 48,363
Change in fair value	(43,790)
Ending balance	$ 4,573

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 10,554		$ 10,554		$ 8,627
Less: accumulated depreciation	(3,912)		(3,912)		(2,372)
Property and equipment, net	6,642		6,642		6,255
Depreciation expense	817	$ 308	1,540	$ 585
Internal-use software
Property, Plant and Equipment [Line Items]
Total property and equipment	8,384		8,384		6,591
Equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	692		692		579
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	0		0		362
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	711		711		586
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 767		$ 767		$ 509

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation and related benefits	$ 10,063	$ 11,855
Commercial and marketing related costs	849	1,821
Professional services	1,161	1,710
Research and development costs	1,707	781
Other	1,291	1,779
Total	$ 15,071	$ 17,946

INDEBTEDNESS - Perceptive Credi

INDEBTEDNESS - Perceptive Credit Facility (Details)			6 Months Ended
	Nov. 30, 2021 $ / shares shares	Jun. 30, 2020 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) warrant $ / shares shares
Debt Instrument [Line Items]
Embedded debt derivative			$ 123,000	$ 675,000	$ 123,000
Common Stock
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares	629,057
Series C Preferred Stock
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares							775,000
Additional warrants (in warrants) | warrant							2
Series C Preferred Stock, Warrant 1
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares							50,000
Series C Preferred Stock, Warrant 2
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares							50,000
Series D Preferred Stock
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares							1,012,672
Warrants exercised (in shares) | shares	1,012,672
Exercise price (in dollars per share) | $ / shares							$ 5.51
Series D-1 Preferred Stock
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares	629,057						65,333
Class A Common Stock
Debt Instrument [Line Items]
Number of common stock into which the class of warrant or right converted (in warrants) | shares	926,232
Exercise price (in dollars per share) | $ / shares	$ 9.87
Line of Credit | Perceptive Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 50,000,000
Interest rate			12.10%
Percentage of principal, payment						3%
Return on prepaid amount							1.5
Percentage of voting stock triggering repayment						35%	35%
Issuance costs						$ 750,000
Minimum aggregate cash balance							$ 5,000,000
Proceeds from issuance of debt		$ 28,500,000
Debt fees and expenses							1,500,000
Line of Credit | Perceptive Credit Facility | Debt Covenant 1
Debt Instrument [Line Items]
Revenues for trailing 12-month period							5,750,000
Line of Credit | Perceptive Credit Facility | Debt Covenant 2
Debt Instrument [Line Items]
Revenues for trailing 12-month period							$ 125,000,000
Line of Credit | Perceptive Credit Facility | LIBOR
Debt Instrument [Line Items]
Variable rate		11%
Floor rate						1%
Line of Credit | Debt, Tranche 1
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 30,000,000
Line of Credit | Debt, Tranche 2
Debt Instrument [Line Items]
Maximum borrowing capacity						10,000,000
Line of Credit | Debt, Tranche 3
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 10,000,000

INDEBTEDNESS - Schedule of Debt

INDEBTEDNESS - Schedule of Debt (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
Total	$ 40,132
Perceptive Credit Facility | Line of Credit
Debt Instrument [Line Items]
Principal	30,000
Less: Debt issuance costs and discount at issuance	(2,646)
Total	$ 27,354

INDEBTEDNESS - Future Minimum P

INDEBTEDNESS - Future Minimum Payments Due (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Remainder of 2022	$ 1,840
2023	3,650
2024	10,603
2025	24,039
Total	40,132
Interest payable	(10,132)
Unamortized debt issuance costs	(2,646)
Current portion of long-term debt	(27,354)	$ (26,993)
Long-term debt	$ 0

LEASE - (Details)

LEASE - (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Jan. 01, 2022 ft²	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Renewal term	5 years		5 years
Rent expense | $	$ 713	$ 733	$ 1,454	$ 1,376
Deferred rent | $						$ 1,007
Weighted average remaining lease term	4 years 10 months 24 days		4 years 10 months 24 days
Weighted average discount rate	10%		10%
Boston, Massachusetts
Lessee, Lease, Description [Line Items]
Area of office space (in sqft)	19,000		19,000		900
San Francisco, California
Lessee, Lease, Description [Line Items]
Area of office space (in sqft)	17,000		17,000
Raleigh, North Carolina
Lessee, Lease, Description [Line Items]
Area of office space (in sqft)	7,700		7,700

LEASES - Maturity Table (Detail

LEASES - Maturity Table (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 1,412
2023	2,912
2024	3,176
2025	2,734
2026 and thereafter	3,878
Total lease payments	14,112
Less: present value adjustment	(3,074)
Present value of total lease liabilities	11,038
Less: current lease liability	(1,821)	$ 0
Long-term operating lease liabilities	$ 9,217	$ 0

LEASES - Operating Leases (Deta

LEASES - Operating Leases (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 2,809
2023	2,912
2024	3,176
2025	2,734
2026 and thereafter	3,879
Total lease payments	$ 15,510

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details)		3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 17, 2021 USD ($)	Jun. 30, 2022 USD ($) license_agreement	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) license_agreement	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Number of license agreements | license_agreement		4		4
Data Foundry Cloud Subscription
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase commitment amount	$ 9,300,000
Purchase commitment period	3 years
Purchase liability		$ 2,983,000		$ 2,983,000
Data Foundry Cloud Subscription | Prepaid Expenses
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase liability		2,331,000		2,331,000
Invention Science Fund I, LLC
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Royalty and maintenance expense		250,000	$ 250,000	500,000	$ 500,000
Red 5 Group, LLC
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Royalty and maintenance expense		62,000	$ 62,000	125,000	$ 125,000
Red 5 Group, LLC | License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Maximum payment, milestone achievement		400,000		$ 400,000
BeHealth Solutions, LLC | License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone based license fee payment						$ 1,000,000	$ 750,000
Useful life of capitalized milestone payments				5 years
Maximum payment, milestone achievement		26,000,000		$ 26,000,000
Waypoint Health Innovations, LLC | License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Upfront payment				1,350,000
Upfront annual payment				250,000
Upfront payment liability		1,011,000		1,011,000
Maximum payment, milestone achievement		$ 2,500,000		$ 2,500,000
Amortization period				5 years
Proceeds from royalties				$ 0

REVENUE AND CONTRACT BALANCES_2

REVENUE AND CONTRACT BALANCES (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Mar. 15, 2022	Dec. 31, 2021
Contract assets
Accounts receivables	$ 490	$ 490		$ 555
Unbilled receivables	4,489	4,489		1,239
Contract liabilities
Deferred revenue - current	680	680		421
Deferred revenue - non-current	26	26		$ 22
Revenue recognized		271
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		271
Pear Therapeutics, Inc | SoftBank Corp.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership percentage			5%
Collaborative Arrangement | SoftBank Corp.
Contract liabilities
Revenue recognized	254	254
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	$ 254	$ 254
Collaborative Arrangement | SoftBank Corp. | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, Remaining Performance Obligation, Amount			$ 600
Collaborative Arrangement | SoftBank Corp. | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, Remaining Performance Obligation, Amount			$ 750

CAPITAL STOCK (Details)

CAPITAL STOCK (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Common stock, authorized (in shares)	690,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, outstanding (in shares)	138,677,770	137,836,028
Common stock, issued (in shares)	138,677,770	137,836,028
Warrants outstanding (in shares)	14,213,267
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2021 shares	Nov. 03, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expenses	$ 3,386	$ 572	$ 6,287	$ 1,035
Conversion ratio	1.47		1.47
Granted in period (in shares) | shares	0		1,016,918	3,857,536
Weighted average grant date fair value of stock options (in dollars per share) | $ / shares			$ 2.49	$ 1.34
Fair value of vested stock options			$ 2,169
Unrecognized compensation costs	$ 23,582		$ 23,582
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Granted in period (in shares) | shares			5,092,531
Unrecognized compensation costs, period of recognition			2 years 5 months 4 days
Unrecognized compensation costs	$ 15,349		$ 15,349
Outstanding common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted in period			$ 2,536	$ 2,743
Unrecognized compensation costs, period of recognition			2 years 11 months 12 days
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant (in shares) | shares						16,727,451
2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant (in shares) | shares	38,891,801		38,891,801		32,000,000
Vesting period			4 years
Percentage of outstanding stock maximum			5%
2021 Incentive Award Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Conversion ratio	1		1

STOCK-BASED COMPENSATION - Comm

STOCK-BASED COMPENSATION - Common Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Stock Options
Beginning balance, options outstanding (in shares)		19,381,975	19,381,975
Granted (in shares)	0		1,016,918	3,857,536
Exercised (in shares)			(841,732)
Canceled and forfeited (in shares)			(1,206,632)
Ending balance, options outstanding (in shares)	18,350,529		18,350,529
Options exercisable (in shares)	8,684,822		8,684,822
Weighted Average Exercise Price
Beginning balance, options outstanding (in dollars per share)		$ 3.02	$ 3.02
Granted (in dollars per share)			4.14
Exercised (in dollars per share)			0.99
Canceled and forfeited (in dollars per share)			5.08
Ending balance, options outstanding (in dollars per share)	$ 3.04		3.04
Options exercisable (in dollars per share)	$ 1.06		$ 1.06
Options outstanding, weighted average remaining contractual life		8 years 1 month 28 days	7 years 8 months 26 days
Options exercisable, weighted average remaining contractual life			6 years 6 months 7 days
Options outstanding, aggregate intrinsic value	$ 6,493		$ 6,493
Options exercisable, aggregate intrinsic value	$ 5,220		$ 5,220

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Units (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Number of Shares
Granted in period (in shares)	0	1,016,918	3,857,536
RSUs
Number of Shares
Beginning balance (in shares)		0
Granted in period (in shares)		5,092,531
Forfeited and canceled (in shares)		(299,090)
Ending balance (in shares)	4,793,441	4,793,441
Weighted Average Fair Value
Beginning balance (in dollars per share)		$ 0
Granted (in dollars per share)		3.67
Forfeited and canceled (in dollars per share)		4.06
Ending balance (in dollars per share)	$ 3.64	$ 3.64

STOCK-BASED COMPENSATION - Valu

STOCK-BASED COMPENSATION - Valuation Assumptions (Details) - Outstanding common stock options	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.09%	1.86%	0.84%
Expected volatility	70.87%	65.69%	70.63%
Expected dividend yield	0%	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 8 months 1 day	5 years 5 months 1 day	5 years 8 months 1 day
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 1 month 13 days	6 years 6 months 25 days	6 years

STOCK-BASED COMPENSATION - Stoc

STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock based compensation expenses	$ 3,386	$ 572	$ 6,287	$ 1,035
Cost of product revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock based compensation expenses	151	7	250	13
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock based compensation expenses	1,294	210	2,599	378
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock based compensation expenses	$ 1,941	$ 355	$ 3,438	$ 644

STOCK-BASED COMPENSATION - ESPP

STOCK-BASED COMPENSATION - ESPP (Details) - Employee Stock - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price percentage	85%
Purchase period	6 months
Discount percentage	15%
Maximum purchase amount	$ 25,000
Total number of shares (in shares)		1,800,000	5,400,000
Number of additional shares allowed (in shares)	3,600,000
Percentage of outstanding stock maximum	5%
Shares issued (in shares)	0

NET INCOME (LOSS) PER SHARE - A

NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2022 shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	32,583,286	49,752,862	16,007,125
Conversion ratio	1.47	1.47
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,821,333	18,350,529	14,880,420
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	153,061	4,793,441	0
Warrants to purchase Legacy Pear common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	0	1,126,705
Private placement warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,013,333	5,013,333	0
Public warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	9,199,934	9,199,934	0
Earn-Out Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	12,395,625	12,395,625	0

NET INCOME (LOSS) PER SHARE - B

NET INCOME (LOSS) PER SHARE - Basic and Diluted Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net income (loss) attributable to common shareholders	$ 5,462	$ (28,201)	$ (18,397)	$ (52,594)
Weighted-average common shares outstanding, basic (in shares)	138,288,357	111,946,894	138,071,377	110,311,459
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ 0.04	$ (0.25)	$ (0.13)	$ (0.48)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ 0.04	$ (0.25)	$ (0.13)	$ (0.48)
Net income (loss) attributable to common shareholders	$ 5,462	$ (28,201)	$ (18,397)	$ (52,594)
Weighted-average common shares outstanding, basic (in shares)	138,288,357	111,946,894	138,071,377	110,311,459
Weighted average number diluted shares outstanding adjustment	9,133,686	0	0	0
Weighted-average common shares outstanding, diluted (in shares)	147,422,043	111,946,894	138,071,377	110,311,459

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event $ in Millions	Jul. 25, 2022 USD ($) position
Subsequent Event [Line Items]
Number of positions eliminated | position	25
Percentage of positions eliminated	9%
Expected costs | $	$ 0.9